Close

Propanc Biopharma, Inc , a clinical stage biopharmaceutical company focused on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, announced that a cooperation agreement has been entered into between the University of Jaén and Propanc to commence the POP1 joint drug discovery program to be co-funded by both parties.

Stem Cell Medicine Ltd. (SCM), a biotechnology company developing new therapies for neurological indications, including mesenchymal stem cells and anti-BMP molecules for the treatment of Multiple Sclerosis, and gene therapy for the treatment of neuropathic pain, has licensed an innovative exosomes based technology for the treatment of neurodegenerative and neuropsychiatric indications, specifically, autism spectrum disorder (ASD).

More Articles ...

Subscribe to our Newsletter
captcha 
Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok